广生堂(300436) - 2022 Q3 - 季度财报

Financial Performance - Revenue for Q3 2022 reached ¥104,961,700.94, an increase of 7.38% compared to the same period last year[4] - Net profit attributable to shareholders was -¥45,270,492.49, a significant decline of 1,218.14% year-on-year[4] - The company reported a basic and diluted earnings per share of -¥0.2842, a decrease of 1,215.74% year-on-year[4] - The net profit for Q3 2022 was a loss of ¥81.64 million, compared to a loss of ¥19.43 million in Q3 2021, reflecting a significant decline in profitability[23] - The total profit for Q3 2022 was a loss of ¥88.66 million, compared to a loss of ¥26.63 million in the same period last year[22] Research and Development - R&D expenses surged to ¥120,149,542.08, representing a 169.27% increase, primarily due to increased spending on innovative drugs[8] - Research and development expenses increased significantly to CNY 54.40 million, a year-on-year growth of 252.33%[11] - Cumulative research and development expenses for the first three quarters reached CNY 120.15 million, a year-on-year increase of 169.27%[11] - The innovative drug GST-HG171 for COVID-19 has shown excellent antiviral efficacy and safety, with clinical trials initiated on October 3, 2022[11] - The innovative drug GST-HG121 for hepatitis B has demonstrated significant efficacy in animal studies, with clinical trials starting on July 26, 2022[12] - The company has multiple ongoing clinical studies for new drugs targeting various diseases, including non-alcoholic fatty liver disease and liver fibrosis[12] Assets and Liabilities - Total assets as of September 30, 2022, amounted to ¥1,508,558,979.65, reflecting a 4.27% increase from the end of the previous year[4] - The company's total liabilities increased to CNY 492,982,617.94 from CNY 396,922,904.17, reflecting a rise of approximately 24.2%[20] - The company's non-current assets totaled CNY 1,053,111,384.06, an increase from CNY 896,876,285.31 at the beginning of the year, reflecting a growth of approximately 17.4%[19] Cash Flow - Cash flow from operating activities showed a net outflow of -¥77,728,318.34, worsening by 789.57% compared to the same period last year[8] - The company reported a net cash outflow from operating activities of approximately ¥77.73 million, worsening from a cash outflow of ¥8.74 million in the previous year[25] - Cash and cash equivalents at the end of Q3 2022 stood at ¥297.96 million, down from ¥442.77 million at the end of Q3 2021, indicating a decrease of 32.6%[26] - The financing activities generated a net cash inflow of approximately ¥143.54 million, a decrease from ¥429.17 million in Q3 2021[26] Shareholder Information - The total number of common shareholders at the end of the reporting period is 18,268[9] - The largest shareholder, Fujian Aohua Group Co., Ltd., holds 22.02% of shares, amounting to 35,068,651 shares, with 23,110,000 shares pledged[9] - The second-largest shareholder, Ye Liqing, holds 8.50% of shares, totaling 13,536,700 shares[9] - The controlling shareholder, Aohua Group, holds 35,068,651 shares, representing 22.02% of the total share capital after the redemption of 12.7 million shares used as collateral for bonds[16] - Aohua Group has pledged a total of 23.11 million shares, which is 65.90% of its holdings, equivalent to 14.51% of the company's total share capital[16] Government Support and Capital Management - The company received government subsidies amounting to ¥2,436,593.33 during the quarter, with a total of ¥6,697,068.83 for the year-to-date[5] - The company approved a capital increase of CNY 30 million to its wholly-owned subsidiary, increasing its registered capital from CNY 140 million to CNY 170 million[14] - The company plans to temporarily use CNY 50 million of idle raised funds to supplement working capital, with a repayment period not exceeding 12 months[14] Operating Costs - The total operating costs for Q3 2022 were approximately ¥446.06 million, an increase of 35.5% compared to ¥329.04 million in Q3 2021[22] - The company generated ¥330.68 million in cash from sales of goods and services, an increase from ¥307.70 million in the same quarter last year[24] - The company reported an investment income of ¥56.03 million, significantly higher than ¥21.89 million in Q3 2021, showing improved performance in investment activities[22]